Literature DB >> 22964478

Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Sune Pedersen1, Rasmus Mogelvang, Mette Bjerre, Jan Frystyk, Allan Flyvbjerg, Soren Galatius, Tor Biering Sørensen, Allan Iversen, Anders Hvelplund, Jan S Jensen.   

Abstract

BACKGROUND: Osteoprotegerin (OPG) is a glycoprotein with a regulatory role in immune, skeletal and vascular systems. Data suggest that high circulating OPG levels are associated with an increased risk of cardiovascular disease. We analyzed the association between OPG and long-term outcome in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI).
METHODS: We included 716 consecutive STEMI patients admitted to a single high-volume invasive heart center from September 2006 to December 2008. Endpoints were all-cause mortality, repeat myocardial infarction, admission due to heart failure and combinations thereof. Median follow-up lasted 27 months (interquartile range: 22-33).
RESULTS: OPG levels exhibited a non-Gaussian distribution and were therefore divided into quartiles. High levels of OPG were significantly associated with a worse outcome. After adjustment for conventional risk factors (e.g. C-reactive protein, estimated glomerular filtration rate, symptom-to-balloon time and troponin I) using Cox regression, OPG remained a significantly independent predictor of death (HR per increase in OPG quartile: 1.28; CI: 1.03-1.59; p = 0.03), repeat myocardial infarction (HR: 1.30; CI: 1.00-1.68; p = 0.05) and admission with heart failure (HR: 1.50; CI: 1.18-1.90; p = 0.001).
CONCLUSION: This study shows that OPG independently predicts long-term outcome in STEMI patients treated with pPCI. Eventually, this knowledge could improve risk stratification and overall outcome.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964478     DOI: 10.1159/000339880

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  8 in total

1.  Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging.

Authors:  E Kastritis; M Gavriatopoulou; M A Dimopoulos; E Eleutherakis-Papaiakovou; N Kanellias; M Roussou; C Pamboucas; S T Toumanidis; E Terpos
Journal:  Blood Cancer J       Date:  2015-06-05       Impact factor: 11.037

Review 2.  The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox

Authors:  Flora Özkalaycı; Öykü Gülmez; Betül Uğur-Altun; Seithikurippu Ratnas Pandi-Perumal; Armağan Altun
Journal:  Balkan Med J       Date:  2018-04-24       Impact factor: 2.021

Review 3.  The relevance of microRNA in post-infarction left ventricular remodelling and heart failure.

Authors:  Mieczysław Dutka; Rafał Bobiński; Jan Korbecki
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

4.  Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes.

Authors:  Atsushi Aoki; Miho Murata; Tomoko Asano; Aki Ikoma; Masami Sasaki; Tomoyuki Saito; Taeko Otani; Sachimi Jinbo; Nahoko Ikeda; Masanobu Kawakami; San-e Ishikawa
Journal:  Cardiovasc Diabetol       Date:  2013-01-09       Impact factor: 9.951

Review 5.  Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.

Authors:  Mette Bjerre
Journal:  Springerplus       Date:  2013-12-06

6.  Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.

Authors:  Thor Ueland; Axel Åkerblom; Tatevik Ghukasyan; Annika E Michelsen; Pål Aukrust; Richard C Becker; Maria Bertilsson; Anders Himmelmann; Stefan K James; Agneta Siegbahn; Robert F Storey; Frederic Kontny; Lars Wallentin
Journal:  J Am Heart Assoc       Date:  2018-01-12       Impact factor: 5.501

7.  Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants.

Authors:  Lena Tschiderer; Gerhard Klingenschmid; Rajini Nagrani; Johann Willeit; Jari A Laukkanen; Georg Schett; Stefan Kiechl; Peter Willeit
Journal:  J Am Heart Assoc       Date:  2018-08-21       Impact factor: 5.501

Review 8.  Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases.

Authors:  Mieczysław Dutka; Rafał Bobiński; Wojciech Wojakowski; Tomasz Francuz; Celina Pająk; Karolina Zimmer
Journal:  Heart Fail Rev       Date:  2021-07-27       Impact factor: 4.654

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.